PSP
REGN icon

Principal Street Partners’s Regeneron Pharmaceuticals REGN Stock Holding History

Principal Street Partners’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-410
Closed -$215K – 343
2025
Q2 		$215K Buy
+410
New +$229K 0.02% 345
2024
Q4 		– Sell
-232
Closed -$244K – 250
2024
Q3 		$244K Hold
232
– – 0.04% 195
2024
Q2 		$244K Hold
232
– – 0.04% 203
2024
Q1 		$226K Hold
232
– – 0.04% 221
2023
Q4 		$204K Buy
+232
New +$191K 0.05% 204

Other funds holding REGN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Principal Street Partners's REGN Position: Q3 2025 in Review

Principal Street Partners sold out of Regeneron Pharmaceuticals (REGN) in Q3 2025, closing a stake of 410 shares — an estimated $215K sold.

Principal Street Partners first reported a position in REGN in Q4 2023 and held it in 5 quarters. The position peaked at $244K in Q3 2024. 1,244 funds tracked by Wall St. Rank hold REGN as of Q3 2025.

  • Principal Street Partners reported no remaining Regeneron Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Principal Street Partners sold 410 Regeneron Pharmaceuticals shares in Q3 2025, an estimated $215K.
  • Principal Street Partners first reported a position in Regeneron Pharmaceuticals in Q4 2023 and held it in 5 quarters.
  • Principal Street Partners's Regeneron Pharmaceuticals position peaked at $244K in Q3 2024.
  • 1,244 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2025.

Based on Principal Street Partners's 13F filing for Q3 2025, filed 14 Nov 2025.